Some may find this interestingIt has no direct relevance to TH or mention of TH, but Dr. Kuravilla runs a top performing health care fund for mutual fund firm Eventide (over the longer term - he points out reasons for recent underperformance). At the end he talks about cancer cells and how they fool the immune system. He points out therapies are in development to address this which he thinks these will be important developments in cancer research. I suspect he does not know anything about TH's TH-1902, which is a problem for TH. He should know about it.
https://go.eventideinvestments.com/biotech-investing-in-2021